Table 2.
Expression level of selected tumor markers measured by IHC staining in DLBCL by HIV infection status
| Tumor marker | HIV-infectedb | HIV-uninfectedb | Pc | |
|---|---|---|---|---|
| Cell-cycle regulator | ||||
| Cyclin E | % tumor cells positivea | 23.2% | 15.4% | 0.29 |
| Mean expression level (SD)d | 1.4 (1.4) | 1.3 (1.1) | ||
| cMYC | 64.3% | 32.1% | <0.01e | |
| 1.5 (1.5) | 0.4 (0.7) | |||
| P27 | 39.2% | 74.7% | <0.01e | |
| 0.5 (0.8) | 1.0 (0.7) | |||
| SKP2 | 8.1% | 10.1% | 0.78 | |
| 0.4 (1.0) | 1.0 (1.0) | |||
| B-cell activator/differentiation | ||||
| BCL6 | % tumor cells positivea | 45.2% | 10.1% | <0.01e |
| Mean expression level (SD)d | 1.5 (1.4) | 0.4 (0.8) | ||
| FOXP1 | 36.0% | 59.5% | <0.01 | |
| 1.2 (1.3) | 1.9 (1.4) | |||
| PKC-β2 | 61.1% | 3.8% | <0.01e | |
| 2.7 (1.7) | 0.5 (0.8) | |||
| CD21 | 1.4% | 1.3% | 1.00 | |
| 0.0 (0.1) | 0.0 (0.1) | |||
| CD10 | 28.8% | 21.5% | 0.46 | |
| 1.1 (1.4) | 0.6 (1.1) | |||
| Apoptosis regulator | ||||
| BCL2 | % of tumor with positivea | 51.4% | 50.7% | 1.00 |
| Mean expression level (SD)d | 1.7 (1.3) | 1.6 (1.5) | ||
| P53 | 16.0% | 10.1% | 0.34 | |
| 0.7 (1.2) | 0.3 (0.8) | |||
| Survivin | 76.8% | 87.3% | 0.13 | |
| 2.8 (1.5) | 2.6 (1.2) | |||
| BAX | 74.7% | 76.0% | 1.00 | |
| 2.6 (1.5) | 2.6 (1.3) | |||
| GAL3 | 26.1% | 45.6% | 0.02 | |
| 1.5 (1.5) | 2.1 (1.8) | |||
| BLIMP1 | 9.9% | 13.8% | 0.62 | |
| 0.3 (0.8) | 0.7 (0.9) | |||
| Others | ||||
| MUM1 | % of tumor with positivea | 58.9% | 13.9% | <0.01e |
| Mean expression level (SD)d | 1.8 (1.5) | 0.5 (0.9) | ||
| Ki-67 | 35.3% | 41.8% | 0.50 | |
| 2.1 (0.8) | 2.2 (1.1) | |||
| CD44 | 86.7% | 55.8% | <0.01e | |
| 2.8 (1.2) | 1.9 (1.5) | |||
| CD30 | 23.6% | 7.7% | <0.01 | |
| 1.0 (1.5) | 0.3 (0.9) | |||
| CD43 | 23.3% | 32.1% | 0.15 | |
| 1.1 (1.6) | 1.7 (1.5) | |||
| LMO2 | 55.4% | 62.0% | 0.42 | |
| 2.0 (1.5) | 2.2 (1.5) | |||
| MMP9 | 41.2% | 19.2% | <0.01 | |
| 2.0 (1.7) | 1.3 (1.3) | |||
| IgM | 53.4% | 38.5% | 0.07 | |
| 2.0 (1.8) | 1.5 (1.9) | |||
| Co-expression phenotype | ||||
| cMYC+ and BCL2+ | 25.3% | 13.9% | 0.07 | |
| cMYC+, BCL2+ and BCL6+ | 7.9% | 1.3% | 0.05 | |
Cutoff value for positivity: cyclin E: 3+; c-MYC: 1+; p27: 1+; SKP2: 3+; BCL6: 2+; FOXP1:2+; PKC-β2: 3+; CD21: 2+; CD10: 2+; BCL2: 2+; p53:2+; survivin: 2+; BAX: 2+; GAL3: 3+; BLIMP1: 2+; MUM1:2+, Ki-67:3+; CD44: 2+; CD30: 2+; CD43: 3+; LMO2: 2+; MMP9: 3+; IgM: 2+.
Number included in each tumor marker analysis varies slightly due to failure of staining in some specimens.
P value obtained from Fisher exact test.
Tumor marker score 0 = 0%–9%, 1 = 10%–24%, 2 = 25%–49%, 3 = 50%–74%, and 4 = ≥75% of DLBCL cells stained positive for the marker.
Statistical significance at P < 0.10 level after adjusting for multiple comparisons using the Bonferroni method (0.10/25 comparisons = 0.004).